$ICUI Cashflow Statement | Understand Stock

$ICUI

$163.20 -$2.76 (1.66%) Close

$ICUI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash and Cash Equivalents, Period Increase (Decrease)
Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss)
Depreciation and amortization
Operatingleaserightofuseassetamortization
Amortization of Inventory Step-up
Operating Lease, Right-of-Use Asset, Amortization Expense
Provision for doubtful accounts
Provision for warranty and returns
Stock compensation
Loss on Disposition of Property Plant Equipment, net
Bond premium amortization
Debt issuance cost amortization
Change in fair value of contingent earn-out
Production Related Impairments or Charges
Sparepartsusage
Income (Loss) from Equity Method Investments
Gain (Loss) on Disposition of Business
Gain (Loss) on Extinguishment of Debt
Other
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Other Operating Assets
Accounts payable
Accrued liabilities
Income taxes, including excess tax benefits and deferred income taxes

Net cash provided by (used in)operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment
Proceeds from Divestiture of Businesses
Proceeds from sale of assets
Intangible asset additions
Business acquisitions, net of cash acquired
Payments to Acquire Equity Method Investments
Purchases of investment securities
Proceeds from sale of investment securities
Net cash used in by investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of long-term debt, net of lender debt issuance costs
Payments of Debt Issuance Costs
Proceeds from Long-term Lines of Credit
Repayments of Short-Term Debt
Repayments of Long-term obligations
Payment of third-party debt issuance costs
Proceeds from exercise of stock options
Payments on finance leases
Payment for Contingent Consideration Liability, Financing Activities
Purchase of treasury stock

Net cash (used in) provided by financing activities
Effect of exchange rate changes on cash
Effect of Exchange Rate on Cash
Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total
CASH AND CASH EQUIVALENTS, beginning of period
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation

SUPPLEMENTAL DISCLSOURE OF CASH FLOW INFORMATION
Cash paid during the year for income taxes
Interest Paid, Excluding Capitalized Interest, Operating Activity
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES
Accounts payable for property, plant and equipment
Noncash Non-compete agreement with associated contingent earn-out liability
Fair value of assets acquired
Cash paid for acquisitions, net of cash acquired
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
Smiths Medical
Total business Combination, Consideration Transferred, Equity Interests Issued and Issuable
Contingent consideration
Goodwill, Period Increase (Decrease)
Goodwill, Acquired During Period
Foreign Infusion System Supplier
Total goodwill, Acquired During Period
Liabilities Assumed
Smiths Medical
International Distributor
Foreign Infusion System Supplier
Issuance of long-term debt to refinance existing credit facility supplemental
Direct payoff of a portion of the existing credit facility
Transfer to Investments

Comments